Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Childs

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
Frontiers in Immunology|September 26, 2024
Alterations in the plasma proteome persist ten months after recovery from mild to moderate SARS-CoV-2 infectionJulio A Huapaya, Salina Gairhe, Shreya Kanth, et al.
The Lancet. Oncology|January 4, 2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialMohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, et al.
Blood|February 28, 2018
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 studyInhye E Ahn, Mohammed Z H Farooqui, Xin Tian, et al.
The Journal of Infectious Diseases|February 21, 2023
Vaccination Ameliorates Cellular Inflammatory Responses in SARS-CoV-2 Breakthrough InfectionsJulio A Huapaya, Jeanette Higgins, Shreya Kanth, et al.
Cell Reports. Medicine|July 9, 2024
Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19Shreya M Kanth, Julio A Huapaya, Salina Gairhe, et al.
The New England Journal of Medicine|April 11, 2020
Compassionate Use of Remdesivir for Patients with Severe Covid-19Jonathan Grein, Norio Ohmagari, Daniel Shin, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
Frontiers in Immunology|September 26, 2024
Alterations in the plasma proteome persist ten months after recovery from mild to moderate SARS-CoV-2 infectionJulio A Huapaya, Salina Gairhe, Shreya Kanth, et al.
The Lancet. Oncology|January 4, 2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialMohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, et al.
Blood|February 28, 2018
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 studyInhye E Ahn, Mohammed Z H Farooqui, Xin Tian, et al.
The Journal of Infectious Diseases|February 21, 2023
Vaccination Ameliorates Cellular Inflammatory Responses in SARS-CoV-2 Breakthrough InfectionsJulio A Huapaya, Jeanette Higgins, Shreya Kanth, et al.
Cell Reports. Medicine|July 9, 2024
Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19Shreya M Kanth, Julio A Huapaya, Salina Gairhe, et al.
The New England Journal of Medicine|April 11, 2020
Compassionate Use of Remdesivir for Patients with Severe Covid-19Jonathan Grein, Norio Ohmagari, Daniel Shin, et al.
Pageof 9